Iran Advances in Regenerative Medicine with Approval of Six Cutting-Edge Therapies

Royan, a leading center for regenerative medicine and cell therapy, has successfully brought six ATMPs to market, Press TV reported. These medicines, based on genes, tissues, or cells, offer innovative treatment options for a wide range of diseases and injuries.

The approvals not only increase access to high-tech treatments for Iranian patients but also reduce the country’s dependence on imported complex medical products. Iran now joins a select group of nations producing 110 advanced cell therapy products, strengthening its scientific influence in West Asia and boosting its knowledge-based economy.

In 2025, 148 ATMPs received global regulatory approval from 12 international authorities. Among them, seven were developed in Iran, propelling the country from 12th to 7th place worldwide in this sector. This represents a dramatic rise from just one licensed regenerative medicine product in the Iranian year 1402 (March 2023–March 2024).

The newly approved products include therapies in cell treatment, tissue engineering, and chimeric antigen receptor (CAR) T-cell therapy, targeting conditions such as vitiligo, graft-versus-host disease (GVHD), cerebral palsy (CP), burns, diabetic foot ulcers, arthritis, and B-cell acute lymphoblastic leukemia (B-cell ALL). Several of these high-tech therapies also hold promising export potential.